Getting started with your GLP-1

You're taking an important step and making a GLP-1 or GIP/GLP-1 part of your journey to the healthiest you. That’s great!

Before you begin, here are some important things you should know to help you use your GLP-1 or GIP/GLP-1 correctly, learn what’s ahead, and kick-start your journey today!

What are GLP-1s?

GLP-1s are a type of medication called a glucagon-like peptide 1 (GLP-1) receptor agonists. These medications are often nicknamed “GLP-1s” for short, and they work by acting like a hormone that your body naturally makes to regulate blood sugar and appetite.

GIP/GLP-1 dual-action medications (short for “glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists”) work in similar ways as GLP-1 medications but target two hormones instead of one to regulate blood sugar and appetite.

You’ll receive one of several types of GLP-1 or GIP/GLP-1, depending on why it has been prescribed for you:

How your medication works

GLP-1s and GIP/GLP-1s are believed to help with weight management in two important ways (Hayes, 2011):

  • They slow down how quickly food leaves your stomach—making you feel full faster and satiated for longer

  • They talk directly to the part of your brain in charge of feeling full—helping you regulate how much you eat

These two effects, when combined with an appropriate diet and exercise, make GLP-1s and GIP/GLP-1s an excellent tool to support healthy weight management. 

GLP-1s and GIP/GLP-1s can also be combined with a healthy diet and exercise to improve blood glucose control in people with type 2 diabetes mellitus. When blood glucose levels are high, GLP-1s cause an increase in a hormone called insulin and a decrease in another hormone called glucagon—a combined effect that lowers overall blood glucose levels (Novo Nordisk, 2022).

How and when to take it

The branded GLP-1s and GIP/GLP-1s prescribed by Ro-affiliated providers come in a prefilled injection pen. The compounded semaglutide and compounded tirzepatide prescribed by Ro-affiliated providers comes in vials that you will draw up into a syringe. With both approaches, you (or someone in your household) will administer the injection of semaglutide under the skin of your stomach, thigh, or arm.  

Be sure to read the instructions that come with the pen before taking your first dose.

The instructions for different forms of GLP-1s and GIP/GLP-1s are very different. Find the steps for the medication you have below.

GLP-1 and GIP/GLP-1 dosing

GLP-1s usually start at a low dose and gradually increase to a dose that will remain steady for the remainder of your treatment.

Follow the instructions from your Ro-affiliated provider for dosing, as they may personalize your plan to your specific needs.

5 tips to get the best results from your medication

Stick to a routine

If you are prescribed semaglutide (Wegovy, Ozempic, or compounded) or tirzepatide (Zepbound or compounded tirzepatide), you can take it on any day of the week, at any time of day, either with or without food. Once you pick a day, stick with that same day each week to make taking your medication a habit. If you are prescribed liraglutide (Saxenda or Victoza), you must take it every day, at any time of day, either with or without food. Once you pick a time of day, stick with that time every day to make taking your medication a habit.

Don’t skip a dose

When life gets busy, it’s very easy to forget to take a medication. But skipping a dose may impact how much benefit you’ll see from your GLP-1 or GIP/GLP-1. . If you’re afraid you’ll forget to use your medication on schedule, there are plenty of tricks to help you remember. You might try setting a phone reminder, marking each dose on your calendar, or taking it right before an activity you do on a regular basis.

Eat a healthy, reduced-calorie diet

All successful weight loss plans require that you decrease how many calories you eat and drink each day—and the same is true if weight management is one of the aims of your treatment. When GLP-1s and GIP/GLP-1s have been studied, participants were told to follow a reduced-calorie diet. That, plus the medication, helped participants lose a significant amount of their bodyweight over time. 

By helping you feel full faster and longer, your medication can make reducing calories easier, but it’s still possible to consume too many even while taking a GLP-1 or GIP/GLP-1.

First, focus on getting used to making your medication part of your routine. Once you do, we’ll be sending you tips on how to shop for healthy foods and make smart changes to the way you eat—all to help you get the most out of your weight loss journey.

Make exercise part of your routine

Like a healthy diet, exercise is an essential part of improving your health. In most studies evaluating GLP-1s and GIP/GLP-1s, participants were instructed to perform moderate exercise (like a brisk walk) for 30 minutes a day, five days a week. But again, for now, focus on getting the hang of taking your medication. Soon, we will send you tips on how to get your body moving so you can see the best results.

Keep an eye on your email

Your experience doesn’t end when your medication is delivered. We want to see you find the most success and satisfaction with your weight loss journey. That’s why we’ll be sending you tips and tricks from our medical content team every week. Each article will be packed with useful insights and support for each step of your journey, so be on the lookout!

Frequently asked questions

Side effects of GLP-1s and GIP/GLP-1s

Tirzepatide (Zepbound and compounded tirzepatide) and oral contraception (birth control pills)

What you should know about how tirzepatide affects birth control

What to do if you’re taking other medications

Who shouldn’t take a GLP-1 or GIP/GLP-1


Sources
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & NN8022-1922 Study Group (2015). Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA, 314(7), 687–699. doi: 10.1001/jama.2015.9676. Retrieved from https://jamanetwork.com/journals/jama/fullarticle/24289560
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England), 397(10278), 971–984. doi: 10.1016/S0140-6736(21)00213-0. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33667417/
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021). Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes & Endocrinology, 9(9), 563–574. Doi: 10.1016/S2213-8587(21)00174-1. Retrieved from https://pubmed.ncbi.nlm.nih.gov/34293304/
Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G. S., Chowansky, A., Zimmer, D., et al. (2011). Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metabolism, 13(3), 320–330. doi:10.1016/j.cmet.2011.02.001. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108145/
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine, 387(3), 205–216. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 
Lilly. 2022. Zepbound PI. Retrieved November 27, 2023 from https://pi.lilly.com/us/zepbound-uspi.pdf
Novo Nordisk. 2021-a. Saxenda PI. Retrieved May 26, 2022 from https://www.novo-pi.com/saxenda.pdf
Novo Nordisk. 2021-b. Wegovy PI. Retrieved April 05, 2022 from https://www.novo-pi.com/wegovy.pdf
Novo Nordisk. 2021-c. Victoza PI. Retrieved May 27, 2022 from https://www.novo-pi.com/victoza.pdf
Novo Nordisk. 2022. Ozempic PI. Retrieved April 05, 2022 from https://www.novo-pi.com/ozempic.pdf
Pi-Sunyer, D., et al. (2015). A randomized, controlled trial of 3.0 mg liraglutide in weight management. The New England Journal of Medicine (NEJM), 373(1), 11–22. doi: 10.1056/NEJMoa1411892. Retrieved from https://www.nejm.org/doi/full/10.1056/nejmoa1411892
Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414. doi: 10.1001/jama.2021.3224. Retrieved from https://jamanetwork.com/journals/jama/fullarticle/2777886
Wilding, J., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine (NEJM), 384(11), 989. doi:10.1056/NEJMoa2032183. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

More from part 1

Strong foundations

These lessons about your medication, discovering your unique Body Story, finding your personal inspiration, and our foundational approach to nutrition are the building blocks for your Ro Body journey.